Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Arch Biopartners Inc ACHFF


Primary Symbol: V.ARCH

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSXV:ARCH)

St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

GlobeNewswire 9 days ago

UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

GlobeNewswire April 3, 2024

Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

GlobeNewswire April 2, 2024

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2

GlobeNewswire March 18, 2024

University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

GlobeNewswire March 15, 2024

Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

GlobeNewswire March 7, 2024

Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury

GlobeNewswire February 27, 2024

Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

GlobeNewswire January 10, 2024

Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

GlobeNewswire January 3, 2024
View More News ››

Opinion & Analysis (TSXV:ARCH)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSXV:ARCH)

More Great News

Arch is on a roll snd just keeps pumping out more great news. We get another Canadian site, and it just happens to be the #1 Heart...
Viking2233 - April 3, 2024

3 more sites

Good newd continues to flow in here. 3 more sites in Turkey now dosing. My best guess the original 3 sites have already dosed about 15...
Viking2233 - April 2, 2024

RJ Analyst

Nothing but total silence from our sole analyst at Raymond James. This analyst has not commented on number of material news releases: 1....
Viking2233 - March 27, 2024

Algorithms

appear still be manipulating this stock. We had a very brief uptick in buying which lifted us to a new 52 week high which was nice to see...
Viking2233 - March 27, 2024

More Great News

Well we finally got the long overdue 3rd party peer review. Now we wait to see how Raymond James Analyst reacts, I betting he will give...
Viking2233 - March 18, 2024

Arch BioPartners - LSALT Peptide Development

Arch believes that LSALT peptide has the potential to deliver a major breakthrough in the treatment of diseases where inflammation...
Riverfolk - March 18, 2024
View more Bullboard ››

Hillcrest Energy Technologies Ltd.

Hillcrest Energy Technologies Ltd.

Hillcrest Energy Technologies is a clean tech innovation company developing high value, high-performance control systems and ...
View More »